Porcine vaccines are biological preparations intended to provide active acquired immunity to pigs against one or several infectious diseases. The major porcine diseases addressed through vaccination include porcine parvovirus, porcine circovirus 2, classical swine fever and porcine reproductive and respiratory syndrome. Advantages of porcine vaccines include prevention of multiple diseases in pigs through a single vaccination, thus reducing treatment costs for farmers.
The global Porcine Vaccines Market is estimated to be valued at US$ 2.4 Bn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Growing investments in R&D for new porcine vaccine formulations is one of the key trends propelling the growth of the global porcine vaccines market. Major market players are focusing on developing novel technologies such as therapeutic DNA vaccines and live-attenuated vaccines with the aim of providing improved efficacy and long lasting immunity to pigs against various infectious diseases. For instance, in 2022, CEVAC entered into a partnership with University of Calgary to develop therapeutic DNA vaccines to protect pigs against Salmonella and porcine reproductive and respiratory syndrome virus (PRRS). Similarly, in 2021, MSD Animal Health received approval for SUPORCINTM, the first live attenuated PRRS vaccine which provides long term strain-specific protection against PRRSV. Such innovations are expected to boost the adoption of advanced porcine vaccines during the forecast period.
SWOT Analysis
Strength: Porcine vaccines have wide acceptance among farmers and pig rearers as it helps prevent infectious diseases in pigs and improve production.
Weakness: High research and development costs associated with development of new vaccines.
Opportunity: Increasing prevalence of viral and bacterial diseases in pigs has created demand for effective vaccines. Emerging economies with growing meat consumption offer new markets.
Threats: Stringent regulations associated with vaccine development and approval processes. Trade barriers imposed by certain countries poses challenges.
Key Takeaways
The global porcine vaccines market is expected to witness high growth. The global Porcine Vaccines Market is estimated to be valued at US$ 2.4 Bn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030.
Regional analysis The Asia Pacific region dominates the market and is expected to grow at the fastest pace due to increased meat consumption, large pig population and rising awareness. The Asia Pacific region dominates the market currently owing to large pig populations and growing demand for pork especially in China and Vietnam. China is the largest pork producer globally. Other fast growing regions include Latin America and Eastern Europe.
Key players in the market focus on developing new and innovative vaccines to prevent major infectious diseases affecting pig farms. Leading players support farmers and veterinarians through educational programs, research partnerships and technical expertise. Partnerships with governments and industry associations help companies launch effective immunization programs. Rising global pork trade has amplified the need for disease control through advanced immunization. Stable funding from stakeholders will help bolster R&D and production capacity over the coming years.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
